Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Modalis Therapeutics Corporation ( (JP:4883) ).
Modalis Therapeutics Corporation reported a non-operating income of 64 million yen due to foreign exchange gains for the fiscal year ending December 31, 2024. This financial update highlights the impact of currency fluctuation on the company’s foreign currency denominated assets, potentially affecting their overall financial performance.
More about Modalis Therapeutics Corporation
Modalis Therapeutics Corporation is a company listed on the Tokyo Stock Exchange, primarily engaged in the biotechnology industry. The company focuses on therapeutic innovations and is known for its advancements in genetic medicine.
YTD Price Performance: -2.94%
Average Trading Volume: 8,379,093
Technical Sentiment Consensus Rating: Buy
Current Market Cap: Yen7.2B
For an in-depth examination of 4883 stock, go to TipRanks’ Stock Analysis page.